Bone Therapeutics is a biopharmaceutical company based in Gosselies, Belgium, developing cell and biologic therapies for orthopaedic indications. Its lead allogeneic cell therapy platform, ALLOB, comprises human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow MSCs and is in two Phase I/IIA proof-of-concept trials for delayed-union fractures and spinal fusion. Patient recruitment for the ALLOB trials was expected to complete in the first half of 2022 with results in the second half of 2022. Its next-generation viscosupplement JTA-004, a patented mix of plasma proteins, hyaluronic acid and a fast-acting analgesic, is in Phase III for knee osteoarthritic pain and the company planned a marketing-authorisation application in the first half of 2022. Bone Therapeutics has a diversified portfolio from pre-clinical immunomodulation programs to mid-to-late stage orthopaedic candidates and is engaging partners to commercialise JTA-004 in Europe, the US and Asia. The company secured a €16M loan from the European Investment Bank to accelerate clinical development and regulatory preparation of ALLOB and JTA-004. Bone Therapeutics develops autologous and allogeneic bone cell therapy products to address high unmet needs in bone fracture repair and prevention. Its lead autologous product PREOB is in pivotal Phase IIB/III trials for osteonecrosis and non-union fractures and in Phase II for severe osteoporosis. The allogeneic off-the-shelf product ALLOB is in Phase I/IIA for delayed-union fractures and lumbar fusion. The company manufactures to GMP standards and holds a portfolio of 11 patent families. Founded in 2006 and headquartered in Gosselies (south of Brussels), Bone Therapeutics is conducting further research to support its clinical programs, including a two-year project to investigate ALLOB’s mode-of-action. Financially, the company received non-dilutive support totaling €5 million for 2015, including an additional €2 million grant announced here, an amount the CEO said equals 13.5% of its IPO proceeds. Bone Therapeutics is a biotechnology company developing cell therapy products containing osteoblastic (bone-forming) cells for minimally invasive treatment of fracture repair and fracture prevention. Its autologous product PREOB is in pivotal Phase IIB/III trials for osteonecrosis and non-union fractures and in Phase II for severe osteoporosis, while its allogeneic “off-the-shelf” product ALLOB is in Phase I/IIA for delayed-union fractures and lumbar fusion. The company runs preclinical programs to optimize manufacturing and broaden indications and administration routes, and it emphasizes GMP manufacturing and a substantial IP estate covering 11 patent families. Recently Bone Therapeutics was granted EUR 3 million in non-dilutive funding from the Walloon Region to support three preclinical research projects over two years. Planned projects include cryopreservation optimization for ALLOB, studies of cell adhesion and chemotaxis, and development of donor bone marrow preselection techniques to improve production yields. The company was founded in 2006 and is headquartered in Gosselies (South of Brussels), Belgium. Bone Therapeutics develops innovative cell therapy products for the treatment of bone diseases, with a lead product, PREOB, in Phase III clinical development for osteonecrosis and non-union fractures. The company intends to use new capital to accelerate its bone cell therapy platform and to sustain the ongoing Phase III program. It is also developing an allogeneic bone cell therapy, ALLOB®, which was expected to enter the clinic in 2013, and MXB, a combined cell‑matrix product for large bone defects currently in preclinical development. Founded in 2006 and led by CEO Enrico Bastianelli, the company is based in Gosselies, Belgium. The articles report no operating metrics such as revenue or user counts.

Total raised

$35M

Funding rounds

5

Latest round

Debt Financing

Latest activity

Jul 2021